Novo Holdings Leads US$21M Series A Financing in BI-OMILQ

  • Funds will be used to support the development of pioneering mammary biotechnology to bring a novel infant feeding option to market that better meets infants’ nutritional needs
  • Syndicate includes leading clean tech and food tech investors

Copenhagen, Denmark – 20 October 2021 – Novo Holdings, a leading international life science investor, today announces it has led the US$21 million Series A financing in BIOMILQ, Inc. (“BIOMILQ”), a first-of-its-kind mammary biotechnology company.

BIOMILQ is developing a novel infant feeding option, derived from human mammary cells, to better meet infants’ nutritional needs and with a lower carbon footprint than traditional bovine-based infant formula. Earlier this year, BIOMILQ announced it had successfully produced a milk product with many of the same macronutrients that are known to be abundantly present in breastmilk in its lab based in Research Triangle Park in North Carolina, US.

Read more

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...

GET IN TOUCH